Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs ...

The abstracts will be available on the AACR 2025 meeting website. The posters will be available online at Erasca.com/science/presentations following the presentations.

Bigger animals didn’t seem to have a greater risk of cancer than smaller ones ... SARAH AMEND: So the elephant has been the poster child for this for a long time, and it has been well published that ...

Anemia and low performance status predict worse survival and greater risk for treatment failure in low-intermediate risk vs ...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer Firs ...

Data evaluating safety and injection feasibility from a Phase 1 study of JNJ-1900 (NBTXR3) in combination nivolumab or ...

Evaxion will present new biomarker and immune data obtained from the ongoing phase 2 trial. These will further add to EVX-01’s already strong clinical data package.

genetics and cancer risk, pre-cancer biology and interception opportunities, inequalities and precision prevention using repurposed drugs. We're inviting attendees to showcase their work and present a ...

Scientists dive into the genomes of whales, elephants, and other animal giants looking for new weapons in the fight against ...

EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers -- EO-1022 is an antibody drug conjugate (ADC) ...